Search

Lynn C Hartmann

age ~73

from Saint Paul, MN

Also known as:
  • Lynn Hartmann
  • Lynn Dale
  • Lynn Hartman

Lynn Hartmann Phones & Addresses

  • Saint Paul, MN
  • Cumberland, WI
  • Frederick, MD
  • Rochester, MN
  • Mazeppa, MN

Work

  • Company:
    Mayo Clinic
  • Address:
    200 1St St Sw, Rochester, MN 55905
  • Phones:
    (507)2842511

Education

  • School / High School:
    Northwestern University The Feinberg School Of Medicine
    1983

Languages

English

Awards

Healthgrades Honor Roll

Industries

Human Resources

Specialities

Oncology • Medical Oncology

Amazon

Clinica Mayo: Guias Del Cancer De La Mujer/ Mayo Clinic: Guide Of Women's  Cancers: Cancer De Mama / Breast Cancer (Spanish Edition)

Clinica Mayo: Guias del Cancer de la Mujer/ Mayo Clinic: Guide of Women's Cancers: Cancer de Mama / Breast Cancer (Spanish Edition)

view source

Book by Hartmann, Lynn C., M.D., Loprinzi, Charles L.


Author
Lynn C., M.D. Hartmann, Charles L. Loprinzi

Binding
Hardcover

Pages
286

Publisher
Editorial Trillas S.A. De C.V.

Publication Date
2005-12-30

ISBN #
9706558209

EAN Code
9789706558206

ISBN #
3

Mayo Clinic Guide To Women's Cancers

Mayo Clinic Guide to Women's Cancers

view source

Mayo Clinic guide to women's cancer.


Binding
Hardcover

Pages
640

Publisher
Mayo Clinic

Publication Date
2005-02-01

ISBN #
189300533X

EAN Code
9781893005334

ISBN #
2

The Mayo Clinic Breast Cancer Book

The Mayo Clinic Breast Cancer Book

view source

From the breast health experts at Mayo Clinic comes a guide to the many aspects of breast cancer—from prevention, to care and coping, to survival, to living with hope. Trustworthy information offered in a spirit of companionship.“This is the best source for readable, up-to-date information—from the ...


Author
Lynn C. Hartmann

Binding
Kindle Edition

Pages
453

Publisher
RosettaBooks

Publication Date
2012-11-16

ISBN #
1

Outcome After Prophylactic Mastectomy in Individuals at High Risk for Breast Cancer: A Combined Clinical-Biological Study.

view source

Author
Lynn Hartmann

Binding
Paperback

Publisher
PN

Publication Date
1995

ISBN #
4

Resumes

Lynn Hartmann Photo 1

Lynn Hartmann

view source
Location:
Greater Minneapolis-St. Paul Area
Industry:
Human Resources

Medicine Doctors

Lynn Hartmann Photo 2

Dr. Lynn C Hartmann, Rochester MN - MD (Doctor of Medicine)

view source
Specialties:
Oncology
Medical Oncology
Address:
Mayo Clinic
200 1St St Sw, Rochester, MN 55905
(507)2842511 (Phone)
Certifications:
Internal Medicine, 1986
Medical Oncology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Northwestern University The Feinberg School Of Medicine
Graduated: 1983
Medical School
University Ia Hosps/Clins
Graduated: 1984
Medical School
University Ia Hosps/Clins
Graduated: 1986
Medical School
Mayo Med Fdn
Graduated: 1986
Lynn Hartmann Photo 3

Lynn Hartmann

view source
Specialties:
Medical Oncology
Work:
Mayo ClinicMayo Clinic Rochester Orthopaedics
200 1 St SW, Rochester, MN 55905
(507)5383270 (phone), (507)2664234 (fax)
Education:
Medical School
Northwestern University Feinberg School of Medicine
Graduated: 1983
Conditions:
Attention Deficit Disorder (ADD)
Languages:
English
Description:
Dr. Hartmann graduated from the Northwestern University Feinberg School of Medicine in 1983. She works in Rochester, MN and specializes in Medical Oncology.
Lynn Hartmann Photo 4

Lynn C Hartmann, Rochester MN

view source
Specialties:
Internal Medicine
Medical Oncology
Gynecology
Work:
Mayo Medical School
200 1St St SW, Rochester, MN 55905
Education:
Northwestern University (1983)
Lynn Hartmann Photo 5

Lynn C Hartmann, Rochester MN

view source
Specialties:
Oncologist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
Northwestern University, Feinberg School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Name / Title
Company / Classification
Phones & Addresses
Lynn Carol Hartmann
Lynn Hartmann MD
Internist
200 1 St SW, Rochester, MN 55905
(507)2842511

Us Patents

  • Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Ovarian Cancer

    view source
  • US Patent:
    7470509, Dec 30, 2008
  • Filed:
    Feb 7, 2003
  • Appl. No.:
    10/361112
  • Inventors:
    Andrew I. Damokosh - West Hartford CT,
    Natalia Iartchouk - Wayland MA,
    Edwin A. Clark - Pennington NJ,
    Karen Lu - Houston TX,
    Lynn Hartmann - Rochester MN,
    Gordon B. Mills - Houston TX,
  • Assignee:
    Millennium Pharmaceuticals, Inc. - Cambridge MA
  • International Classification:
    C12Q 1/68
  • US Classification:
    435 6, 536 231, 536 235, 435 4
  • Abstract:
    The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
  • Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers

    view source
  • US Patent:
    7871775, Jan 18, 2011
  • Filed:
    Dec 17, 2007
  • Appl. No.:
    12/002783
  • Inventors:
    Edwin Clark - Ashland MA,
    Tallessyn Grenfell-Lee - Cambridge MA,
    Karen Lu - Houston TX,
    Lynn Hartmann - Rochester MN,
    Jeffrey L. Brown - Arlington MA,
    Gordon B. Mills - Houston TX,
  • Assignee:
    Millennium Pharmaceuticals, Inc - Cambridge MA
    Mayo Foundation for Medical Edication and Research - Rochester MN
    Board of Regents, The University of Texas System - Austin TX
  • International Classification:
    C12Q 1/68
  • US Classification:
    435 6, 536 231
  • Abstract:
    The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers. ” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers. ” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
  • Immunity To Folate Receptors

    view source
  • US Patent:
    8486412, Jul 16, 2013
  • Filed:
    Jun 1, 2007
  • Appl. No.:
    12/303054
  • Inventors:
    Keith L. Knutson - Rochester MN,
    Lynn C. Hartmann - Rochester MN,
    Kimberly R. Kalli - Dover MN,
    Christopher J. Krco - Rochester MN,
  • Assignee:
    Mayo Foundation for Medical Education and Research - Rochester MN
  • International Classification:
    A61K 38/10
    C07K 4/12
  • US Classification:
    4241851, 4241841, 4242771, 514 192, 514 193, 514 214, 514 215, 530326, 530806
  • Abstract:
    This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FRα immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.
  • Novel Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers

    view source
  • US Patent:
    20030143552, Jul 31, 2003
  • Filed:
    Feb 8, 2002
  • Appl. No.:
    10/071510
  • Inventors:
    Edwin Clark - Ashland MA,
    Tallessyn Grenfell-Lee - Cambridge MA,
    Karen Lu - Houston TX,
    Lynn Hartmann - Rochester MN,
    Jeffrey Brown - Arlington MA,
  • Assignee:
    Millennium Pharmaceuticals, Inc. - Cambridge MA
  • International Classification:
    C12Q001/68
    G01N033/574
  • US Classification:
    435/006000, 435/007230
  • Abstract:
    The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of sensitivity and resistance markers. These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
  • Method For Cancer Prognosis Using Cellular Folate Vitamin Receptor Quantification

    view source
  • US Patent:
    20090081710, Mar 26, 2009
  • Filed:
    Mar 30, 2006
  • Appl. No.:
    11/887438
  • Inventors:
    Philip Stewart Low - West Lafayette IN,
    Lynn C. Hartmann - Rochester MN,
    Christopher Paul Leamon - West Lafayette IN,
    Phil Ronald Ellis - West Lafayette IN,
  • Assignee:
    Purdue Research Foundation - West Lafayette IN
  • International Classification:
    G01N 33/574
  • US Classification:
    435 723
  • Abstract:
    The invention relates to a method for determining a prognosis for a cancer by quantifying vitamin receptor expression on the cancer cells. The method comprises the steps of quantifying vitamin receptor expression on the cancer cells, and determining a prognosis for the cancer. The invention also relates to methods and kits for determining the presence of vitamin receptors on cancer cells to select patients that should be treated with a therapy that utilizes vitamin receptor targeting and to develop a treatment regimen for such patients. The invention further relates to kits for performing the methods.
  • Novel Compositions And Methods For Identification, Assessment, Prevention, And Therapy Of Ovarian Cancer

    view source
  • US Patent:
    20090136961, May 28, 2009
  • Filed:
    Nov 18, 2008
  • Appl. No.:
    12/313196
  • Inventors:
    Andrew I. Damokosh - West Hortford CT,
    Edwin A. Clark - Ashland MA,
    Karen Lu - Houston TX,
    Lynn Hartmann - Rochester MN,
    Gordon B. Mills - Houston TX,
  • Assignee:
    Millennium Pharmaceuticals, Inc. - Cambridge MA
    Board of Regents - Austin TX
    Mayo Foundation for Medical Education and Research - Rochester MN
  • International Classification:
    C12Q 1/68
  • US Classification:
    435 6
  • Abstract:
    The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
  • Quantitation Of Lobular Involution For Breast Cancer Risk Prediction

    view source
  • US Patent:
    20100311106, Dec 9, 2010
  • Filed:
    Jan 21, 2009
  • Appl. No.:
    12/863889
  • Inventors:
    Lynn C. Hartmann - Rochester MN,
    Carol Reynolds - Rochester MN,
    Kevin P. McKian - Rochester MN,
  • International Classification:
    C12Q 1/02
  • US Classification:
    435 29
  • Abstract:
    Methods for determining risk of developing breast cancer are described.
  • Assessing Atypical Hyperplasia Patients For The Risk Of Developing Breast Cancer

    view source
  • US Patent:
    20110136129, Jun 9, 2011
  • Filed:
    Dec 6, 2010
  • Appl. No.:
    12/960894
  • Inventors:
    Lynn C. Hartmann - Rochester MN,
    Marlene Frost - Burnsville MN,
    Carol Reynolds - Rochester MN,
    Vernon Pankratz - Rochester MN,
  • International Classification:
    C12Q 1/68
  • US Classification:
    435 614
  • Abstract:
    This document provides methods and materials involved in assessing the risk of developing breast cancer in patients with atypical hyperplasia. For example, methods and materials for using the level of Ki67 expression (e.g., percent Ki67cells or Ki67 staining intensity) to determine if a patient with atypical hyperplasia has an increased risk of developing breast cancer within an early phase from diagnosis (e.g., within ten years of biopsy) or an increased risk of developing breast cancer at a late phase from diagnosis (e.g., at a point more than ten years of biopsy) are provided.

News

Preventive Surgery For Women At High Risk Of Breast And Ovarian Cancer

Preventive surgery for women at high risk of breast and ovarian cancer

view source
  • "Women whose families have been marked by excess breast and ovarian cancer are at higher risk of developing those diseases over their lifetime," says lead author and Mayo Clinic oncologist Lynn Hartmann, M.D. "Although these women can reduce their risk considerably through preventive mastectomies an
  • Date: Feb 03, 2016
  • Category: Health
  • Source: Google
Atypical Hyperplasia Increase Cancer Of The Breast Risk

Atypical hyperplasia increase cancer of the breast risk

view source
  • The lead author of the research and Mayo Clinics oncologist Lynn Hartmann studied 698 of women. All of the women possessed atypical hyperplasia and had been biopsied between 1967 and 2001 at Mayo Clinic. The observations made by the team revealed that after a period of 5 years, about 7 percent of t
  • Date: Jan 03, 2015
  • Category: Health
  • Source: Google
Benign Atypical Hyperplasia Not So Benign After All As It Carries High Breast ...

Benign Atypical Hyperplasia Not So Benign After All as it Carries High Breast ...

view source
  • We need to do more for this population of women who are at higher risk, such as providing the option of MRI screenings in addition to mammograms and encouraging consideration of anti-estrogen therapies that could reduce their risk of developing cancer," said Lynn Hartmann the study's lead author in
  • Date: Jan 03, 2015
  • Category: Health
  • Source: Google
Risk Of Breast Cancer Increases With Atypical Hyperplasia

Risk of breast cancer increases with atypical hyperplasia

view source
  • Lynn Hartmann is an oncologist at Mayo Clinic and the lead author of this study that followed 698 women. All the women had atypical hyperplasia and had been biopsied at Mayo Clinic between 1967 and 2001. The team observed that after five years, around 7% of these women had developed the disease. Aft
  • Date: Jan 01, 2015
  • Category: Health
  • Source: Google
Women With Atypia Lesions Have A Higher Risk Of Developing Breast Cancer ...

Women with Atypia Lesions Have a Higher Risk of Developing Breast Cancer ...

view source
  • "By providing better risk prediction for this group, we can tailor a woman's clinical care to her individual level of risk," said Lynn Hartmann, one of the researchers, in a news release. "We need to do more for this population of women who are at higher risk, such as providing the option of MRI scr
  • Date: Jan 01, 2015
  • Category: Health
  • Source: Google
Common Breast Biopsy Finding May Be More Dangerous Than Thought

Common Breast Biopsy Finding May Be More Dangerous Than Thought

view source
  • While experts have always known that atypical hyperplasia increases the risk of breast cancer, the new finding gives women with the condition more solid information about the extent of the risk, said study researcher Dr. Lynn Hartmann, a professor of oncology at the Mayo Clinic in Rochester, Minn.
  • Date: Dec 31, 2014
  • Category: Health
  • Source: Google
'Benign' Breast Mass Has A Greater Risk For Cancer

'Benign' breast mass has a greater risk for cancer

view source
  • It gives you the scale of the risk, and it turns out to be a bit higher than the estimated risk that comes from some popular methods used to try to predict a womans likelihood of developing breast cancer, said Dr. Lynn Hartmann of the Mayo Clinic who led the review.
  • Date: Dec 31, 2014
  • Category: Health
  • Source: Google

Doctors May Need to Revise How They Evaluate Breast Biopsy Results

view source
  • "We were not so sure what to do with ALH before," said study researcher Dr. Lynn Hartmann, a professor of oncology at the Mayo Clinic, in Rochester, Minn. "This is suggesting, treat it the same as ADH. What we are saying is, it doesn't matter which kind [of abnormality]."
  • Date: Jan 30, 2014
  • Category: Health
  • Source: Google

Mylife

Lynn Hartmann Photo 6

Lynn Hartmann

view source
Tags:
Female, Age: 39
Locality:
Tallahassee, FL
Lynn Hartmann Photo 7

Lynn Hartmann

view source
Tags:
Female, Age: 31, Branch Manager
Locality:
Jacksonville, FL
Lynn Hartmann Photo 8

Lynn Hartmann

view source
Tags:
Male, Age: 57
Locality:
San Marcos, TX
Lynn Hartmann Photo 9

Kay Lynn Hartmann (Teske)

view source
Tags:
Female, Age: 42
Locality:
Boulder, CO
Lynn Hartmann Photo 10

Lynn Hartmann

view source
Tags:
Female, Age: 56, Elementary Teacher
Locality:
Aurora, CO
Lynn Hartmann Photo 11

Lynn Hartmann

view source
Tags:
Male, Age: 59
Locality:
Fort Lauderdale, FL
Lynn Hartmann Photo 12

LYNN HARTMANN

view source
Tags:
Age: 39
Locality:
Tallahassee, FL
Lynn Hartmann Photo 13

lynn hartmann

view source
Tags:
Female, Age: 48
Locality:
Fresno, CA

Youtube

Mayo Clinic Transform 2013 Symposium, "Scienc...

Lynn Hartmann, M.D., Mayo Clinic breast cancer expert shares research ...

  • Category:
    Science & Technology
  • Uploaded:
    17 Oct, 2013
  • Duration:
    17m 35s

Classmates

Lynn Hartmann Photo 14

Kay Lynn Hartmann, St. lo...

view source
Kay Lynn Hartmann 1989 graduate of Benilde-St. Margarets High School in St. louis park, MN
Lynn Hartmann Photo 15

Lynn Hartmann, St. louis,...

view source
Lynn Hartmann 1960 graduating class of Hazelwood East High School in St. louis, MO
Lynn Hartmann Photo 16

Kara Lynn Hartmann | Clas...

view source

Facebook

Lynn Hartmann Photo 17

Amelia Elizabeth Lynn Har...

view source
Friends:
Justin Arens, Kalyb Davis, Courtney Bluske, Natalie Rindt, Andrew Hoppert
Lynn Hartmann Photo 18

Lynn Hartmann

view source
Friends:
Caitlin Marie O'Leary, Lucie Serwylo, Uneeda Brewer, Lisa Bramson Harbert
Lynn Hartmann Photo 19

Lynn Hartmann

view source
Lynn Hartmann Photo 20

Chelby Lynn Hartmann

view source
Lynn Hartmann Photo 21

Lynn Hartmann

view source
Lynn Hartmann Photo 22

Lynn Hartmann

view source

Get Report for Lynn C Hartmann from Saint Paul, MN, age ~73
Control profile